| Document Date: 2015-03-16 01:05:14
Open Document File Size: 414,36 KBShare Result on Facebook
Company Sanofi-Aventis Australia Pty Ltd / The PBAC / Genzyme Corporation / Meeting 9 Sponsor’s Comment Genzyme / Sanofi company / / Country Australia / / Currency USD / / Event Product Issues / Product Recall / FDA Phase / / Facility Consumer Comments facility / / IndustryTerm fingolimod accounting / infection management / / MedicalCondition disease / cognitive impairment / pain / progressive / chronic disease / fatigue / high disease activity / Relapsing-Remitting Multiple Sclerosis / multiple sclerosis / infection / MS / / MedicalTreatment retreatment / / Person Submission / / Position representative / / Product Rebif / concern / CAMMS03409 / Alemtuzumab / T2 / / PublishedMedium The Lancet / / Technology Trial ID Protocol / MRI / /
SocialTag |
Public Summary Document – November 2014 PBAC MeetingALEMTUZUMAB solution for infusion, 10 mg/ mL; Lemtrada®; Genzyme (Sanofi-Aventis Australia Pty Ltd). 1